Evaluation of Treatment of Patients with SARS-CoV-2 in line with Literature

Karaarslan, Numan; Doğan, Mustafa; Yılmaz, İbrahim; Bilir, Bülent; Hacioglu, Fatma; Onar, Lutfi Cagatay; Özbek, Hanefí

doi:10.35514/mtd.2020.29

Cited by 1 publication

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmaceutical preparations such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, azithromycin, clarithromycin, moxifloxacin, acetylsalicylic acid, enoxaparin, dexamethasone, and paracetamol were used as mono or combined in the routine treatment of 2019-nCov cases examined in this review. Besides the aforementioned drugs, the use of atazanavir [17] or tocilizumab [5] have been reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

“…Studies on 2019-nCov [2][3][4] have reported typical clinical symptoms such as fever, cough, diarrhea, and fatigue. Furthermore, some anomalies have been reported in the characteristic laboratory and radiological examinations [5]. In some studies, it has been discovered that SARS-CoV-2 infection may cause damage to the central nervous system, especially the olfactory bulb, even when the infection is still in its early stages [6,7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies?

Ateş

Yılmaz

Karaarslan

et al. 2022

J Infect Dev Ctries

View full text Add to dashboard Cite

The objectives of this study were to determine the prevalence of cerebrovascular diseases caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, and to assess the pharmacological agents used in such cases as reported in the literature. Patient files were retrospectively scanned to determine the prevalence of neurological symptoms of the central nervous system (headache, dizziness, lack of smell and taste, numbness in arms and legs, change in consciousness, muscle weakness, loss of urine and stool control) and cerebrovascular diseases (ischemic cerebrovascular diseases, cerebral venous sinus thrombosis, intracerebral hemorrhage, subarachnoid/subdural hemorrhage) in 2019 novel coronavirus (2019-nCoV) disease (COVID-19) cases (n = 20,099). The diagnostic laboratory, radiology examinations and treatments applied to these cases were recorded. The data from studies presenting cerebrovascular diseases associated with SARS-Cov-2, which constituted 0.035% of all cases, were systematically evaluated from electronic databases. During the treatment of cerebrovascular diseases, it was discovered that high doses of enoxaparin sodium anti-Xa are combined with apixaban or acetylsalicylic acid or clopidogrel or piracetam, and mannitol, in addition to SARS-CoV-2 treatment modalities. While neurological symptoms of the central nervous system are uncommon in cases of SARS-CoV-2 infection, cerebrovascular diseases are far less common, according to the findings of this study. Acute cerebral ischemia was discovered to be the most common cerebrovascular disease associated with SARS-CoV-2. The mortality rate increases with the association between SARS-CoV-2 and cerebrovascular disease.

show abstract

Section: Discussionmentioning

confidence: 99%